About Orikine Bio

Orikine Bio develops engineered cytokines with unique biological properties to treat immune-mediated diseases, focusing on enhancing therapeutic efficacy and safety. The company aims to provide targeted therapies that improve patient outcomes by harnessing the potential of cytokines in immune modulation.

```xml <problem> Immune-mediated diseases present significant therapeutic challenges due to the complex and often systemic nature of immune dysregulation. Current treatments often lack specificity, leading to broad immunosuppression and increased risk of adverse effects, while failing to fully address the underlying disease mechanisms. </problem> <solution> Orikine Bio engineers cytokines with enhanced and unique biological properties to create targeted therapies for immune-mediated diseases. By precisely modulating the immune system, Orikine Bio's engineered cytokines aim to improve therapeutic efficacy and safety compared to traditional approaches. These novel cytokines are designed to selectively interact with specific immune cells and pathways, promoting a more balanced and controlled immune response. This targeted approach seeks to minimize off-target effects and maximize the therapeutic benefit for patients suffering from a range of immune-related disorders. The company's focus is on developing transformative therapies that can reshape the lives of patients worldwide. </solution> <features> - Engineered cytokines with tailored receptor binding profiles for enhanced specificity - Modified cytokine structures designed for improved stability and pharmacokinetic properties - Targeted immune modulation to selectively activate or suppress specific immune cell populations - Preclinical validation demonstrating superior efficacy and safety compared to wild-type cytokines </features> <target_audience> Orikine Bio's primary target audience includes patients suffering from immune-mediated diseases, as well as pharmaceutical companies seeking innovative therapeutic options in the immunology space. </target_audience> ```

What does Orikine Bio do?

Where is Orikine Bio located?

Orikine Bio is based in Barcelona, Spain.

When was Orikine Bio founded?

Orikine Bio was founded in 2022.

How much funding has Orikine Bio raised?

Orikine Bio has raised 6780000.

Who founded Orikine Bio?

Orikine Bio was founded by Christian Pangratz.

Christian Pangratz - CEO

Location

Barcelona, Spain

Founded

2022

Funding

6780000

Employees

12 employees

Major Investors

Ministry of Science and Innovation of Spain

Looking for specific startups?

Try our free semantic startup search

Orikine Bio

Score: 100/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

orikine.bio 700+

Crunchbase

Founded 2022 – Barcelona, Spain

Funding

Estimated Funding

$6.8M+

Major Investors

Ministry of Science and Innovation of Spain

Team (10+)

Christian Pangratz

CEO

Company Description

Problem

Immune-mediated diseases present significant therapeutic challenges due to the complex and often systemic nature of immune dysregulation. Current treatments often lack specificity, leading to broad immunosuppression and increased risk of adverse effects, while failing to fully address the underlying disease mechanisms.

Solution

Orikine Bio engineers cytokines with enhanced and unique biological properties to create targeted therapies for immune-mediated diseases. By precisely modulating the immune system, Orikine Bio's engineered cytokines aim to improve therapeutic efficacy and safety compared to traditional approaches. These novel cytokines are designed to selectively interact with specific immune cells and pathways, promoting a more balanced and controlled immune response. This targeted approach seeks to minimize off-target effects and maximize the therapeutic benefit for patients suffering from a range of immune-related disorders. The company's focus is on developing transformative therapies that can reshape the lives of patients worldwide.

Features

Engineered cytokines with tailored receptor binding profiles for enhanced specificity

Modified cytokine structures designed for improved stability and pharmacokinetic properties

Targeted immune modulation to selectively activate or suppress specific immune cell populations

Preclinical validation demonstrating superior efficacy and safety compared to wild-type cytokines

Target Audience

Orikine Bio's primary target audience includes patients suffering from immune-mediated diseases, as well as pharmaceutical companies seeking innovative therapeutic options in the immunology space.